Comparing two conditioning regimens for stem cell transplant in T-cell acute lymphoblastic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial compares two chemotherapy conditioning regimens (BuCy and TBICy) used before a stem cell transplant for patients with T-cell acute lymphoblastic leukemia. The goal is to see which regimen leads to better outcomes after the transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 2 years and 55 years or younger.
- You are having your first stem cell transplant from a donor (allogeneic).
- You are generally able to care for yourself (ECOG performance status 0-3).
- You do not have any other cancer.
- You have not had a previous stem cell transplant or CAR T-cell therapy.
- You do not have an uncontrolled infection, severe organ problems, or are pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a risk-adapted conditioning regimen (chemotherapy and/or radiation given before transplant) for people with certain blood cancers or bone marrow disorders who need a stem cell transplant from a donor. The goal is to tailor the conditioning strength to each patient’s risk, which may help improve outcomes and reduce side effects.
This clinical trial tests a new combination of chemotherapy drugs (called TmBU) before a stem cell transplant for people with high-risk or relapsed acute leukemia. The goal is to see if this conditioning regimen works better and is safe for patients who need a transplant.
This study compares two types of stem cell transplants for adults with T-ALL: one using a half-matched donor alone, and one using a half-matched donor plus umbilical cord blood. The goal is to see which approach gives better results with fewer side effects.
This trial compares two drug combinations used before a stem cell transplant to see which is safer and more effective for people with acute myeloid leukemia (AML) that is in remission but still has minimal residual disease (MRD). The goal is to help prevent the leukemia from coming back after transplant.
This trial tests two different chemotherapy and radiation plans (conditioning regimens) given before a stem cell transplant from a matched donor. Both are followed by the same drugs to prevent graft-versus-host disease. The goal is to find which regimen works better for people with blood cancers.
This study tests two types of radiation-based conditioning (TBI or TMLI) before a stem cell transplant from a matched sibling donor, in children with ALL that is in remission. The goal is to see which approach works better and is safer.
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.